BPT Crunch

Companies on the Cutting Edge of Healthcare Innovations

back to Marketplace


BMSystems logo

France based

Understanding the causal mechanisms of a disease while finding the most adapted solutions and effective biomarkers are our objectives.
With our proprietary CADI™ Discovery analytical platform, BMSystems’ team generates novel, fully informed, disruptive concepts from scientific, medical & health data, providing new diagnostic, therapeutic and prevention solutions for medicine.


AI Companies (Drug Discovery)  

R&D Platform

Computer-Assisted Deductive Integration drug discovery platform (CADI)™ based on heuristic non-mathematical models to generate novel hypotheses from scientific, medical & health data. The platform includes several components for data acquisition & mining, data organization & structuring, an integrative engine, and model representation & visualization tool. According to the companies presentation, it augments human scientist’s capacity (Architect) with artificial intelligence capacity (Engineer).


Read more


Clinical  |  Visit website

CADI-T1031: BM-Systems has discovered and offers the world's first therapeutic solution for CFS-Immune Dysfunction (ID). This proprietary therapeutic protocol has successfully completed the proof-of-concept stage and will enter Phase II clinical trials with our confidential development partner.

Clinical  |  Visit website

CADI-T3021: Our Parkinson's disease pathogenesis and clinical progression model links aging-associated gradual decline in mitochondrial function to specific pathogenic mechanisms of cardiovascular, neurological and metabolic origins, depending on the evolution of specific biological contexts. The proof of concept trial of our innovative therapy for Parkinson’s disease is being prepared to be tested in human subjects with our confidential partner.

Clinical  |  Visit website

CADI-T4031: Metabolic syndrome is related to the organism’s selective utilization of energy sources. Mitochondrial adaptation to specific energy sources depends on genetic/ epigenetic and environment-induced mechanisms. Depending upon underlying contexts, these may become dysregulated, giving rise to different pathogenic aspects of metabolic syndrome. The proof of concept therapeutic protocol for Metabolic Syndrome is being prepared for human trials by our confidential partner.

Clinical  |  Visit website

Alzheimer's Disease early diagnostics
CADI-D3041: BMSystems’ understanding of AD origination in the entorhinal cortex and its course of progression through the different neuronal networks, as well as the contribution of neurological functional units (neurons, astrocytes, dendritic cells, etc.) to the progression of the pathology, allows us to identify biomarkers, together with their means of detections, that could predict or increase alertness for identifying AD at its very early stages of progression.

Clinical  |  Visit website

Malnutrition & Metabolic Disorders: India
CADI-T4021: Chronic and long pervading malnutrition in India results in epigenetic and metabolic changes leading to chronic, transgenerational anaemia and autophagy. The major consequences are children being born very small and severely underweight who, in later life, will develop major pathologies such as wasting, stunting, cardiovascular disorders, etc. Rather than seeking to pharmacologically address these pathologies, aiming to attenuate their origins, particularly during pregnancy, together with their later-in-life consequences, might constitute a more effective form of intervention. This collaborative program with the IISER Center of Excellence in Epigenetics in Pune, India, led to the formulation of an effective, extremely low-cost therapeutic approach and the incorporation of Arbuza Regenerate PVT.LTD. for its further development and distribution.




No services posted yet